Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nelly Malenkovich is active.

Publication


Featured researches published by Nelly Malenkovich.


Nature Immunology | 2001

PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Yvette Latchman; Clive Wood; Tatyana Chernova; Divya Chaudhary; Madhuri Borde; Irene Chernova; Yoshiko Iwai; Andrew J. Long; Julia Brown; Raquel Nunes; Edward A. Greenfield; Karen Bourque; Vassiliki A. Boussiotis; Laura Carter; Beatriz M. Carreno; Nelly Malenkovich; Hiroyuki Nishimura; Taku Okazaki; Tasuku Honjo; Arlene H. Sharpe; Gordon J. Freeman

Programmed death 1 (PD-1)–deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4+ T cells. At low antigen concentrations, PD-L2–PD-1 interactions inhibit strong B7-CD28 signals. In contrast, at high antigen concentrations, PD-L2–PD-1 interactions reduce cytokine production but do not inhibit T cell proliferation. PD-L–PD-1 interactions lead to cell cycle arrest in G0/G1 but do not increase cell death. In addition, ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone. PD-L expression was up-regulated on antigen-presenting cells by interferon γ treatment and was also present on some normal tissues and tumor cell lines. Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L–PD-1 pathway in regulating T cell responses.


Nature | 2001

ICOS is critical for CD40-mediated antibody class switching

Alexander J. McAdam; Rebecca J. Greenwald; Michele A. Levin; Tatyana Chernova; Nelly Malenkovich; Vincent Ling; Gordon J. Freeman; Arlene H. Sharpe

The inducible co-stimulatory molecule (ICOS) is a CD28 homologue implicated in regulating T-cell differentiation. Because co-stimulatory signals are critical for regulating T-cell activation, an understanding of co-stimulatory signals may enable the design of rational therapies for immune-mediated diseases. According to the two-signal model for T-cell activation, T cells require an antigen-specific signal and a second, co-stimulatory, signal for optimal T-cell activation. The co-stimulatory signal promotes T-cell proliferation, lymphokine secretion and effector function. The B7–CD28 pathway provides essential signals for T-cell activation, but does not account for all co-stimulation. We have generated mice lacking ICOS (ICOS-/- ) to determine the essential functions of ICOS. Here we report that ICOS-/- mice exhibit profound deficits in immunoglobulin isotype class switching, accompanied by impaired germinal centre formation. Class switching was restored in ICOS-/- mice by CD40 stimulation, showing that ICOS promotes T-cell/B-cell collaboration through the CD40/CD40L pathway.


Journal of Immunology | 2000

Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells

Alexander J. McAdam; Tammy T. Chang; Anna E. Lumelsky; Edward A. Greenfield; Vassiliki A. Boussiotis; Jonathan S. Duke-Cohan; Tatyana Chernova; Nelly Malenkovich; Claudia Jabs; Vijay K. Kuchroo; Vincent Ling; Mary Collins; Arlene H. Sharpe; Gordon J. Freeman

The inducible costimulatory (ICOS) molecule is expressed by activated T cells and has homology to CD28 and CD152. ICOS binds B7h, a molecule expressed by APC with homology to CD80 and CD86. To investigate regulation of ICOS expression and its role in Th responses we developed anti-mouse ICOS mAbs and ICOS-Ig fusion protein. Little ICOS is expressed by freshly isolated mouse T cells, but ICOS is rapidly up-regulated on most CD4+ and CD8+ T cells following stimulation of the TCR. Strikingly, ICOS up-regulation is significantly reduced in the absence of CD80 and CD86 and can be restored by CD28 stimulation, suggesting that CD28-CD80/CD86 interactions may optimize ICOS expression. Interestingly, TCR-transgenic T cells differentiated into Th2 expressed significantly more ICOS than cells differentiated into Th1. We used two methods to investigate the role of ICOS in activation of CD4+ T cells. First, CD4+ cells were stimulated with beads coated with anti-CD3 and either B7h-Ig fusion protein or control Ig fusion protein. ICOS stimulation enhanced proliferation of CD4+ cells and production of IFN-γ, IL-4, and IL-10, but not IL-2. Second, TCR-transgenic CD4+ T cells were stimulated with peptide and APC in the presence of ICOS-Ig or control Ig. When the ICOS:B7h interaction was blocked by ICOS-Ig, CD4+ T cells produced more IFN-γ and less IL-4 and IL-10 than CD4+ cells differentiated with control Ig. These results demonstrate that ICOS stimulation is important in T cell activation and that ICOS may have a particularly important role in development of Th2 cells.


Journal of Experimental Medicine | 2000

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freeman; Andrew J. Long; Yoshiko Iwai; Karen Bourque; Tatyana Chernova; Hiroyuki Nishimura; Lori Fitz; Nelly Malenkovich; Taku Okazaki; Michael C. Byrne; Heidi F. Horton; Lynette A. Fouser; Laura Carter; Vincent Ling; Michael R Bowman; Beatriz M. Carreno; Mary Collins; Clive Wood; Tasuku Honjo


Archive | 2001

Pd-l2 molecules: novel pd-1 ligands and uses therefor

Gordon J. Freeman; Irene Chernova; Tatyana Chernova; Nelly Malenkovich; Clive Wood


Archive | 2000

Novel b7-4 molecules and uses therefor

Gordon J. Freeman; Vassiliki A. Boussiotis; Tatyana Chernova; Nelly Malenkovich


Archive | 2000

Nucleic acids encoding costimulatory molecule B7-4

Gordon J. Freeman; Vassiliki A. Boussiotis; Tatyana Chernova; Nelly Malenkovich


Archive | 2006

B7-4 polypeptides and uses therefor

Gordon J. Freeman; Vassiliki A. Boussiotis; Tatyana Chernova; Nelly Malenkovich


Archive | 2006

B7-4 Antibodies and uses therefor

Gordon J. Freeman; Vassiliki A. Boussiotis; Tatyana Chernova; Nelly Malenkovich


Archive | 2007

Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1

Gordon J. Freeman; Irene Chernova; Tatyana Chernova; Nelly Malenkovich; Clive Wood

Collaboration


Dive into the Nelly Malenkovich's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vassiliki A. Boussiotis

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Beatriz M. Carreno

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge